Medication

Rinvoq (Upadacitinib)

Rinvoq is a once-daily pill for severe eczema that has not responded to other systemic treatments. It works fast and it works well. It carries the JAK inhibitor boxed warning for serious infections, cancer, heart attack, clots and death, and it needs regular blood tests.
At a Glance

Rinvoq (upadacitinib) is an oral JAK inhibitor taken once a day. In dermatology it is approved for refractory moderate to severe atopic dermatitis — eczema — in people 12 and older whose disease is not controlled by other systemic drugs, including biologics. It is also approved for psoriatic arthritis and several rheumatologic and gut conditions. It is one of the most effective eczema drugs available and it works remarkably fast, often calming itch within days. It carries a boxed warning covering serious infection, death, cancer, heart attack, stroke and blood clots, and it requires TB screening and ongoing bloodwork.

Key Facts

AKAUpadacitinib. Rinvoq LQ is the oral liquid form used in children
Drug ClassOral JAK inhibitor (selective for JAK1)
Rx or OTCPrescription only, usually through a specialty pharmacy
Typical StrengthEczema — 15 mg once daily, increased to 30 mg if needed. Adults 65 and over: 15 mg only
Time to WorkItch often improves within a few days; skin clearance builds over 4 to 16 weeks
Evidence LevelStrong for atopic dermatitis. Among the most effective options that exist
ImportantBoxed warning. Oral JAK inhibitors are linked to serious infections, higher death rates, cancer, major heart events and blood clots. Latent tuberculosis must be tested for and treated before you start, and blood counts, liver tests and cholesterol are monitored during treatment.

How It Works

Janus kinases — JAKs — are enzymes sitting on the inside of your cells, right behind the receptors where inflammatory signals arrive. When a signal such as IL-4, IL-13 or IL-31 lands on the outside of a cell, JAK enzymes carry the message inward and tell the cell's nucleus to switch on inflammation.

Upadacitinib blocks that relay, with a preference for JAK1. Because so many different inflammatory messages route through JAK1, blocking it turns down a lot of signals at once. That is why it works on eczema faster and more broadly than a drug that neutralizes a single messenger — Dupixent, for instance, blocks two specific signals from the outside.

IL-31 is the itch signal, and it runs through JAK1. That is why itch on Rinvoq often improves within days, well before the rash looks better. For people who have not slept properly in years, that is frequently the thing they notice first.

The trade-off is the same breadth. JAK signaling is also how your immune system coordinates its response to viruses, to cancerous cells, and to infections. Damping it broadly is what produces the boxed warning.

What It Treats

Moderate evidence
Upadacitinib is an oral JAK inhibitor for moderate to severe atopic dermatitis, including severe hand involvement. It requires ongoing blood monitoring.

Who It's For & Who It's Not

Who it's for

People 12 and older with moderate to severe eczema that has already failed other systemic treatments — including biologics like Dupixent — or where those are not appropriate. The label is specific about this: Rinvoq is not a first systemic drug for eczema.

People whose dominant problem is unbearable itch. Nothing else works this quickly on itch.

People who want a pill instead of an injection, and who accept the trade-off in monitoring and risk.

People with psoriatic arthritis who have failed a TNF blocker.

Who it's not for

Anyone with an active serious infection, or with active or untreated latent tuberculosis.

Anyone with severe liver impairment.

People who are pregnant. Upadacitinib can harm a developing baby; pregnancy status is checked before starting and effective contraception is required during treatment and for a period after.

People with a history of blood clots, heart attack, stroke, or lymphoma — not an absolute bar in every case, but a serious mark against it, and there are safer options.

Current and former smokers, and people over 65, carry higher risk from this class. That is a real conversation, not a formality.

How to Take It

How to take it
  • One tablet once a day, with or without food, at roughly the same time each day. Swallow it whole — do not split, crush or chew it.
  • For eczema, adults under 65 and adolescents 12 and older weighing at least 40 kg: start at 15 mg once daily. If that is not enough, your dermatologist may raise it to 30 mg once daily. If 30 mg is still not working, the label says to stop rather than push higher. Once you are controlled, the aim is the lowest dose that keeps you there.
  • Adults 65 and older: 15 mg once daily, and no higher. The increased risk in older patients is why.
  • If you miss a dose, take it when you remember unless it is nearly time for the next one. Do not double up.
Before your first dose
  • This is a real workup, not a formality:
  • A tuberculosis test. If it is positive, latent TB is treated before you start.
  • Hepatitis B and C screening. Rinvoq is not recommended if you have active hepatitis B or C.
  • A complete blood count. You cannot start if your lymphocytes are under 500, your neutrophils under 1,000, or your hemoglobin under 8.
  • Liver function tests.
  • A pregnancy test, if you can become pregnant.
  • Vaccines brought up to date — including Shingrix, which matters here because shingles is genuinely more common on JAK inhibitors.
Cost, insurance and the specialty pharmacy
  • Rinvoq's list price is very high — comparable to a biologic, well into five figures a year — and there is no generic.
  • It usually comes from a specialty pharmacy, though as an oral drug it can sometimes be filled at a retail pharmacy depending on your plan.
  • Prior authorization is guaranteed. Because the label restricts Rinvoq to eczema that has already failed other systemic therapy, insurers will want documentation that you tried and failed Dupixent, cyclosporine, methotrexate or similar. Expect one to four weeks and often an initial denial. Appeals succeed frequently.
  • A manufacturer copay program can bring commercial-insurance out-of-pocket cost down to very little. It cannot be used with Medicare or Medicaid; on those plans, ask about foundation grants.
  • Do not let your prescription lapse over a paperwork gap. Stopping abruptly usually means the eczema comes back within weeks.

What to Avoid

Alcohol does not directly interact, but since liver enzymes are monitored on this drug, heavy drinking makes that harder to interpret.

Live vaccines
No MMR, varicella, yellow fever, live nasal flu spray or oral typhoid while you are on Rinvoq. Get any you need before you start. Non-live vaccines are fine and important — the inactivated flu shot, COVID vaccines, pneumococcal, and especially Shingrix.
Strong CYP3A4 inhibitors
such as ketoconazole, itraconazole and clarithromycin raise upadacitinib levels. Your dose may need adjusting.
Strong CYP3A4 inducers
such as rifampin lower the levels and can make it stop working.
Other JAK inhibitors, biologics, and strong immune suppressants
including azathioprine and cyclosporine. Do not combine them.
Grapefruit juice
affects the same enzyme pathway. Occasional glasses are unlikely to matter; regular heavy intake is worth avoiding.
Pregnancy
Upadacitinib can harm a fetus. Use effective contraception during treatment and for a period after your last dose — ask your prescriber for the specific interval.

Side Effects

Common and expected
  • Upper respiratory infections — colds, sinus infections, sore throats.
  • Acne. Genuinely common on upadacitinib, and it surprises people. It is usually mild to moderate and treatable in the ordinary ways; it is rarely a reason to stop.
  • Nausea.
  • Headache.
  • Cold sores and other herpes simplex flares.
  • Raised creatine phosphokinase (a muscle enzyme) on blood tests, usually without symptoms.
  • Raised cholesterol.
  • Cough, fever, tiredness.
Tell your doctor
  • Shingles — a painful blistering rash in a band on one side of the body. It is more common on JAK inhibitors, and it is treated far better if you call early.
  • Any infection that is not clearing on its own.
  • New or worsening acne that is bothering you. It is manageable, and you should not just put up with it.
  • Unusual bruising or unusual tiredness — these can reflect a drop in blood counts.
  • A new or changing skin lesion. Non-melanoma skin cancers have been reported.
  • Muscle pain or dark urine.
Stop and get care
  • This drug carries a boxed warning — the FDA's strongest. It applies to the whole class of oral JAK inhibitors, and it covers five things:
  • Serious infections. People taking JAK inhibitors have been hospitalized and have died from infections including tuberculosis, shingles, and invasive fungal infections. TB that has been dormant in your body for years can wake up.
  • Death. In a large safety study of rheumatoid arthritis patients over 50 with a heart risk factor, a different JAK inhibitor was linked to more deaths, including sudden cardiac death, than a TNF blocker was.
  • Cancer. Lymphoma and other cancers have been reported. In that same rheumatoid arthritis study, the JAK inhibitor was linked to more cancers than the comparison drug. Smokers and former smokers were at higher risk.
  • Heart attack and stroke. Also more common in that study than with a TNF blocker, again especially in smokers and former smokers.
  • Blood clots. Deep vein thrombosis, pulmonary embolism (a clot in the lung), and arterial clots. Some have been fatal.
  • Here is the honest framing, because this warning frightens people out of a drug that helps them. The study behind most of it was done in older rheumatoid arthritis patients with existing cardiovascular risk, taking a different drug. Whether the same numbers apply to a healthy 30-year-old with eczema or alopecia is genuinely unknown. It is not nothing, and it is not a reason to panic. What it does mean: if you smoke, are over 50, have had a clot, a heart attack, a stroke or a cancer, the calculation changes and you should have that conversation explicitly with your dermatologist.
  • Get urgent care right away for:
  • Swelling, pain, warmth or redness in one leg — a possible deep vein clot.
  • Sudden shortness of breath, chest pain, or coughing up blood — a possible clot in the lung.
  • Chest pressure, arm or jaw pain, sudden weakness on one side, slurred speech, or a drooping face — signs of a heart attack or stroke.
  • A high fever with shaking chills, a spreading hot painful patch of skin, or a cough with night sweats and weight loss.
  • A painful blistering rash in a band on one side of the body — shingles, which is more common on this drug and is treated best if caught early.
  • Also stop and get help for a severe allergic reaction — swelling of the face, lips or tongue, hives, or trouble breathing.

Monitoring

This drug needs real monitoring. If your prescriber is not ordering these, ask why.

Before you start:
tuberculosis test (blood or skin) with treatment of latent TB first; hepatitis B and C screening; complete blood count; liver function tests; pregnancy test if applicable; vaccinations updated including Shingrix.
Lipids at about 12 weeks
Upadacitinib raises total, LDL and HDL cholesterol. The label specifically says to check lipids around 12 weeks after starting and then follow standard cholesterol guidelines. Elevated LDL generally responds to a statin — it is manageable, not a reason to stop.
Blood counts, ongoing
Neutrophils, lymphocytes and hemoglobin are checked at baseline and periodically after. Treatment is paused if neutrophils fall below 1,000, lymphocytes below 500, or hemoglobin below 8.
Liver enzymes, ongoing,
checked periodically along with the blood count. In practice most dermatologists run labs around 4 to 12 weeks after starting and then every 3 months or so, though the label leaves the exact interval to clinical judgment.
Tuberculosis, yearly
or after a known exposure — a negative test before you started does not settle the question permanently.
Skin checks
Annual full-skin examinations are sensible given the reported non-melanoma skin cancers.
Cardiovascular risk
Blood pressure, smoking status and cholesterol matter more on this drug than on a biologic. If you smoke, this is the drug that gives you the strongest medical reason to stop.

How Long Until It Works

Fast — faster than anything else in eczema.

Itch often eases within 2 to 4 days. Many people say sleep is the first thing that changes.

Skin starts clearing within 2 weeks, with substantial improvement by 4 weeks and the best result around 16 weeks.

If 15 mg is not doing enough by around 8 to 12 weeks, the dose can go to 30 mg (in people under 65). If 30 mg is not working, the label says to stop rather than continue.

For psoriatic arthritis, joint symptoms usually improve within a few weeks.

That speed is the main reason people choose Rinvoq over a biologic, and it is a fair reason. It is also why some people are willing to accept the monitoring and the warnings.

What Happens When You Stop

Rinvoq controls eczema. It does not cure it.

It leaves your system quickly — this is a small-molecule pill, not a long-lasting antibody. That cuts both ways. If you develop a problem, the drug is gone within days. But if you stop, the eczema and the itch tend to return quickly too, often within a couple of weeks, and sometimes back to full severity within a month.

There is no evidence of a dangerous rebound in the way that stopping oral steroids can cause, but the practical return of symptoms is fast enough that people notice it sharply. Do not stop abruptly on your own if you can avoid it — plan the change with your dermatologist and have your topical routine or next drug ready.

If you restart later, it typically works again. There are no antibodies to build up against a small molecule.

If you stop because of side effects or because the risk profile does not suit you, reasonable alternatives for eczema include Dupixent, topical tacrolimus, topical steroids, and narrowband UVB phototherapy.

Who should not take it+

Do not take Rinvoq if:

You have an active serious infection, including active tuberculosis

You have untreated latent tuberculosis

You have severe liver impairment

You are pregnant, or could become pregnant and are not using effective contraception

You are allergic to upadacitinib or anything in the tablet

Weigh it very carefully, with your dermatologist, if you are over 65, smoke or used to smoke, have had a heart attack, stroke or blood clot, or have a history of cancer. Do not combine it with another JAK inhibitor, a biologic, or a potent immune suppressant.

FAQ+
Should the boxed warning scare me off?Not automatically, but you should understand it. The warning comes largely from a safety study in rheumatoid arthritis patients over 50 with cardiovascular risk factors, using a different JAK inhibitor. Whether the same risk applies to a 25-year-old with severe eczema and no other health problems is genuinely unknown. What is clear is that risk is not evenly distributed: age, smoking, prior clots and prior cancer all shift it substantially. Have that conversation specifically rather than reacting to the label in the abstract.
How fast does it stop the itch?Usually within a few days — sometimes the first night. This is the single most striking thing about the drug and the reason many people stay on it.
Why is my acne worse?Acne is a well-recognized and fairly common side effect of upadacitinib. It is not a sign of anything going wrong. It usually responds to ordinary acne treatment; talk to your dermatologist rather than putting up with it.
Rinvoq or Dupixent?Dupixent is an injected biologic with no boxed warning and no required bloodwork; it is slower but safer-looking on paper. Rinvoq is a pill, works faster, and clears more people — but with a boxed warning and ongoing monitoring. The label puts Rinvoq after Dupixent for a reason, and insurers enforce that. If Dupixent works for you, there is no reason to switch.
Do I need blood tests?Yes, genuinely. Blood counts, liver enzymes and cholesterol before starting and periodically after, plus TB screening before and about yearly. This is not a drug you take and forget about.
Can I get vaccines?Non-live vaccines yes, and Shingrix in particular is worth getting because shingles is more common on JAK inhibitors. Avoid live vaccines: MMR, chickenpox, yellow fever, nasal flu spray, oral typhoid. Get any live vaccines before you start.
Can I take it if I'm pregnant or trying?No. Upadacitinib can harm a developing baby. Pregnancy is checked before you start and effective contraception is required during treatment and for a period afterward — ask your prescriber for the exact interval for your situation.
What does it cost?List price is very high and there is no generic. With commercial insurance and the manufacturer copay program, many people pay very little. On Medicare, copay cards are not allowed and costs can be significant. Expect prior authorization requiring proof you failed other systemic treatments first.
Can I drink alcohol?There is no direct interaction. But your liver enzymes are being monitored, so heavy drinking muddies the picture and is worth moderating.
What happens if I just stop?The eczema usually comes back within a few weeks, sometimes fast. Plan the stop rather than doing it abruptly.
Is it approved for alopecia areata or vitiligo?No. In dermatology, Rinvoq's approvals are atopic dermatitis and psoriatic arthritis. For alopecia areata the approved oral JAK inhibitors are Olumiant and Litfulo; for vitiligo it is topical Opzelura.